Research graph
References from Clinical Efficacy and Safety of Topical Roflumilast in Psoriasis: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Joint American Academy of Dermatology–National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis in Pediatric Patients
10.1016/j.jaad.2019.08.049 · 2020 · External reference
Psoriasis
10.1016/s0140-6736(14)61909-7 · 2015 · External reference
Joint AAD‐NPF Guidelines of Care for the Management and Treatment of Psoriasis With Awareness and Attention to Comorbidities
10.1016/j.jaad.2018.11.058 · 2019 · External reference
Psoriasis
10.1016/s0140-6736(20)32549-6 · 2021 · External reference
Trial of Roflumilast Cream for Chronic Plaque Psoriasis
10.1056/nejmoa2000073 · 2020 · External reference
Maximizing Patient Adherence for Optimal Outcomes in Psoriasis
10.1111/j.1468-3083.2011.04060.x · 2011 · External reference
Oral Roflumilast for Psoriasis: A Real‐World 24‐Week Prospective Cohort Study
10.1080/09546634.2025.2464107 · 2025 · External reference
The Preclinical Pharmacology of Roflumilast—A Selective, Oral Phosphodiesterase 4 Inhibitor in Development for Chronic Obstructive Pulmonary Disease
10.1016/j.pupt.2010.03.011 · 2010 · External reference
Roflumilast for Chronic Plaque Psoriasis
10.1001/jama.2022.14663 · 2022 · External reference
The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews
10.1136/bmj.n71 · 2021 · External reference
RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials
10.1136/bmj.l4898 · 2019 · External reference
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial
2025 · External reference
Once‐Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double‐Blind, Vehicle‐Controlled Phase Iib Study
10.1093/bjd/ljad182 · 2023 · External reference
Effect of Roflumilast Cream Vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS‐1 and DERMIS‐2 Randomized Clinical Trials
10.1001/jama.2022.15632 · 2022 · External reference
A Multidimensional Assessment of the Burden of Psoriasis: Results From a Multinational Dermatologist and Patient Survey
10.1111/bjd.16332 · 2018 · External reference
Treatment of Skin Inflammation With Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated With Skin Inflammation and Skin Architecture Changes
10.1124/jpet.116.232819 · 2016 · External reference
Translated Aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
10.1016/j.ad.2024.01.009 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
10.1007/s40261-024-01368-w · 2024 · External reference
Patient Perspectives In the Management of Psoriasis: Results From the Population‐Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
10.1016/j.jaad.2013.12.018 · 2014 · External reference
Increased Severity of Itching, Pain, and Scaling In Psoriasis Patients Is Associated With Increased Disease Severity, Reduced Quality of Life, and Reduced Work Productivity
2015 · External reference
Psoriasis in Special Localizations
10.5114/reum.2018.80718 · 2018 · External reference
Choosing Topical Corticosteroids
2009 · External reference
Topical Therapy in Psoriasis
10.4103/ijd.ijd_422_23 · 2023 · External reference
Unresolved reference
External reference
10.1016/j.jaad.2024.03.030
10.1016/j.jaad.2024.03.030 · External reference
